Femasys is trading at $2.10, up 5.00%, with no clear company-specific catalyst identified.
- On October 8, Femasys announced it will exhibit its fertility portfolio at the ASRM congress October 24–28; the announcement provides no clear evidence it caused the intraday rise.
- Biotech stocks were broadly weaker, with XBI down 2.04%, and broader markets were lower. These moves do not explain the rise, and no stronger company-specific catalyst linking news to the move was identified.